Main factors influencing long-term outcomes of liver transplantation in 2022

doi:10.4254/wjh.v15.i3.321

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5172)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

228

WORD

HTML

2819

Figures (1-1)

374

Tables (1-3)

388

Sum=3846

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

166

Download

353

Sum=519

Publishing Process of This Article

Item

Count

Browse

235

Download

418

Sum=653

Mar 27, 2023 (publication date) through Dec 31, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Mar 27, 2023; 15(3): 321-352
Published online Mar 27, 2023. doi: 10.4254/wjh.v15.i3.321

Table 2 Maintenance immunosuppressants main adverse effects

Drug class	Adverse effects
CNI	Nephrotoxicity[283], recurrence of HCC[188,284], risk of de novo neoplasia[285-287], new onset diabetes mellitus (TAC more than CyA)[288,289], hypertension (CyA more than TAC)[290], dyslipidemia[291] (CyA more than TAC)[292], neurotoxicty[293], weight gain[294,295]
Antimetabolites	Leukopenia, thrombocytopenia, gastrointestinal disturbances (MMF and AZA) diarrhea, CMV reactivation (MMF)[296], pancreatitis, hepatotoxicity, risk of de novo neoplasia (AZA)[296,297]
mTORi	Leukopenia, dyslipidemia[298,299], cutaneous and mucosal alterations[300], wound complications, lymphocele[301], hypertension[302]

CNI: Calcineurin inhibitors; HCC: Hepatocellular carcinoma; TAC: Tacrolimus; CyA: Cyclosporine; MMF: Mycophenolate mofetil; AZA: Azathioprine; mTORi: Mammalian target of Rapamicin inhibitors.

Citation: Fuochi E, Anastasio L, Lynch EN, Campani C, Dragoni G, Milani S, Galli A, Innocenti T. Main factors influencing long-term outcomes of liver transplantation in 2022. World J Hepatol 2023; 15(3): 321-352
URL: https://www.wjgnet.com/1948-5182/full/v15/i3/321.htm
DOI: https://dx.doi.org/10.4254/wjh.v15.i3.321